Date: December 13, 2017
Last Revision: June 15, 2018

If your question is not answered with these resources, please email:

NIH RPPR FAQs includes answers to the following:

A. General
B. RPPR Module
C. RPPR Data
E. Reporting Publications
F. Participant Data
G. Reporting Foreign Collaborations, Personnel, and Dollars
H. Progress Report Additional Materials (PRAM)
I. Final RPPR

CTSA Program Specific RPPR FAQs related to:



Technology Transfer/IRB/IACUC

Clinical Trials



If components were consolidated (including budget) to simplify reporting but maintained separate component narratives within the RPPR structure, may grantees “unbundle” the component budgets and structure them in a way that more closely aligns with their programs?

Please include each programmatic component with its accompanying budget to accurately reflect your CTSA Program hub as presented in the competing grant application.  Please use the appropriate titles for the RPPR components as indicated in the relevant funding opportunity announcement.

What amounts should be used as the budget targets for the CTSA Program RPPR for the UL1, KL2 and TL1 mechanisms? Are grantees required to report the National Research Service Award (NRSA) stipend increase effective for the current fiscal year for pre- and postdoctoral scholars and trainees?

The budget target amounts for the UL1, KL2 and TL1 should be based on the committed level as indicated in the most recent Notice of Award. Grantees are permitted to request to re-budget between the UL1, KL2 and TL1 components only during the RPPR type 5 submission/review process. When re-budgeting funds between components, the total award commitment for all three components should not exceed the total (UL1, KL2, TL1) committed level. The one exception to this is the NRSA stipend. The RPPR should be submitted using the most recently published NRSA policy guide (NOT-OD-16-047). Any policy announcements changing the NRSA rates after RPPR submission will be reflected by an administrative action by NCATS. Grantees should not re-budget funds from the UL1 or KL2 component to cover an increase in the NRSA rates.  Any increase in the NRSA rates is considered an increase in award above the committed level.

When a sub-award/consortium is added to one or more components under the UL1 RPPR, the system will not calculate the sum of sub-awards into the overall budget. Will the system carry over the sum of what is entered in the components boxes in section H.F.5?

The system will carry over the sum entered in the components’ budget section H.F.5 for all sub-award/consortium budgets. Ensure that the figure entered in section H.F.5 for each component’s sub-award/consortium is correct, as the system will not calculate this amount automatically.

How should cost-sharing be addressed? Is it acceptable to state the total direct cost dollar amount of the cost sharing at the end of highlights section?

The voluntary institutional commitment should be addressed in a similar format to which it was portrayed in the competing application. If the competing application included an itemized breakdown of budget items covered through institutional cost share, then this breakdown should be provided in the RPPR budget justification for the relevant components. If the cost share was presented in the competing application as a lump sum and there are no changes to the committed level, then this could be presented in the highlights section. Note: Any significant change to the level of cost share commitment or usage of these funds requires prior approval.


Should the highlights, milestones and challenges report for non-grant-funded components be included in the RPPR?

Highlights, milestones and challenges should be reported in the Overall component of the RPPR.  Non-grant funded components may be included in the description of the CTSA Program grantee institution in the overall component.  Refer to the question above regarding cost share reporting.  Do not create additional components for activities that are supported solely by the institution.

Is a project narrative required for the Admin Core?


Several of the UL1 component instructions appear to be items uploaded in the UL1 overall section. For example, Section B.2 in UL1 components says to follow CTSA Program-specific instructions. However, these instructions say to upload the milestones, highlights and challenges report, evaluation report and revisions/supplements. Shouldn’t these materials be uploaded in the UL1 overall and not the UL1 component?

Each key function/service/resource should be reported as a separate component with its own sections A through H. Instructions for additional component reporting are in section 7.6.2 of the NIH General RPPR Instructions; please follow them carefully. Note: Some of the sections and questions do not apply at the individual component level, and those should be marked accordingly (e.g., Section D. Participants).

Are cover letters still required for each sub-award, and if so, where would they be uploaded in the RPPR?

Cover letters for sub-awards are not required when submitting an RPPR.

The CTSA Program-specific instructions state that grantees need to complete sections A-H for each component. Is it A-H on the regular RPPR instructions or A-H on the special CTSA Program instructions for the UL1 overall?

The CTSA Program-specific instructions are to be used in conjunction with the NIH RPPR instructions. To comply with these two sets of instructions, create separate components for the overall CTSA Program project and for each key function/resource/service.  Follow the RPPR CTSA Program-specific instructions and the NIH RPPR instructions, specifically section 7.6.2, Component Instructions.

There are separate sections of B.3 Competitive Revisions/Administrative Supplements for the title, specific aims and the accomplishments of the supplement.  Should grantees include accomplishments, challenges and status of milestones in the “Accomplishments” text box for section B.3?  If so, are all three of these items to be addressed within the 700-character limit?

Yes. Please address revisions/supplements in the B.3 text box within the designated 700-character limit.  Note that supplements that have been awarded to the UL1 to support an individual’s training, education and career development must provide additional information and be uploaded as an attachment in G.1., Special Notice of Award and Funding Opportunity Reporting Requirements.  Please see the RPPR CTSA Program-specific instructions for additional information.

Technology Transfer/IRB/IACUC

The CTSA Program Specific RPPR Instructions indicate that grantees should include the i-EDISON report number for any CTSA Program-related inventions in question C.4.  Question C.4 is a yes/no question, with no upload option. When reporting any CTSA Program-related inventions, should grantees upload the i-EDISON report number along with the Investigational New Drug/Investigational Device Exemption report in C.5.a, Other Products, if applicable?



As part of the CTSA Program RPPR submission, are National Clinical Trial numbers (NCT#s) required? If so, when?

Yes, however, only CTSA Program-supported clinical trials must be reported in the CTSA Program RPPR.  All NIH-funded clinical trials are expected to register and submit results information to, as per the “NIH Policy on Dissemination of NIH-Funded Clinical Trial Information” for competing applications and contract proposals submitted on or after 1/18/2017 .  For more information please see:

Note that the CTSA Program cannot support clinical trials beyond Phase IIb.

Should information on clinical trials, inclusion enrollment reports and registration be included in the CTSA Program RPPR only for NIH-defined clinical trials directly supported by the CTSA Program or for any clinical trial that meets the NIH definition of clinical trial that is supported by the CTSA Program?

Only clinical trials directly supported by the U, T and K mechanisms that meet the NIH definition of clinical trial should be reported.  For more information see:


If CTSA Program-related pilot projects are supported by the institution and not CTSA Program dollars, should they be reported in the RPPR?

Yes if the original grant application described their pilot program as being funded by the CTSA Program and by the institution.  Please provide information on institutional support and commitment in the reporting period and any proposed modifications for the coming year in the appropriate section. All institutional support and commitment reflected in a particular budget must be clearly stated and properly justified.

Section B.4 of the CTSA Program-specific instructions includes requested information for training and professional development opportunities under the UL1 mechanism. Should CTSA Program grantee institutions report UL1-funded training and professional development incurred by staff?

CTSA Program awardees may include such individuals as study coordinators, research assistants and investigators who take coursework to expand their expertise in clinical and translational science. Topics may include recruitment methods, biostatistics, regulatory science, ethics and/or clinical study design. In addition, there may be certificate programs offered in clinical and translational science, which are not supported under the K or T mechanisms. Finally, workshops supported through the UL1 to foster collaboration, share best practices or review standards for pilot projects may be included.

Should publications for non-grant-funded activities be included in the RPPR?


Are there any plans to deploy an “autosave” feature in the future? Will a template be provided to gather information in the order required by the RPPR?

NIH continues development of the RPPR system and will alert the community as progress is made via notices in the NIH Guide. At this time, NCATS is unaware of any plans for an automatic save feature. The information required in the RPPR is essentially the same information required in previous years, and the order in which data are submitted is not prescribed. The NIH RPPR instructions and the CTSA Program-specific instructions from NCATS should provide sufficient detail to gather the required information. Some suggested templates for PDF attachments have been included in the CTSA Program-specific instructions; however, these are not required.

Is the RPPR required for the final closeout report from institutions with awards ending in 2017 that are submitting a new application?

Effective February 9, 2017, if the recipient organization has submitted a renewal application on or before the date by which a Final Research Performance Progress Report (Final-RPPR) would be required for the current competitive segment, then submission of an “Interim-RPPR” via eRA Commons is now required.   Based on this requirement, the NIH will discontinue the policy for renewal applications whereby, “whether funded or not,” the progress report contained in the renewal application may serve in lieu of a separate final progress report.   The Interim-RPPR must be submitted via the eRA Commons no later than 120 calendar days from the period of performance end date.   For more information please see the Guide Notice NOT-OD-17-037.

A Final Progress Report is required when the competing renewal is not submitted and is required no later than 120 days after the project end date.

Both the Interim RPPR and the Final RPPR are currently identical in process and information required. The difference between the two is when and where they are made available to initiate and submit. The Interim RPPR link will be made available to the Signing Official (SO) in the Status screen when a grant is eligible for submission of a Competing Renewal application.

Further guidance is provided through the scenarios below outlining the process of when to submit a Final or Interim-RPPR.

Scenario Status of Competing Renewal Application Workflow Process
1 Competing Renewal not submitted Submit a Final-RPPR no later than 120 calendar days from the period of performance end date.
2 Competing Renewal submitted Submit an Interim-RPPR no later than 120 calendar days from the period of performance end date. If the competing renewal is funded, NIH will treat the Interim-RPPR as the annual performance report for the final year of the previous competitive segment.
3 Competing Renewal submitted but not funded Submit an Interim-RPPR no later than 120 calendar days from the period of performance end date. If the competing renewal is not funded, NIH will treat the Interim-RPPR as the institution’s Final-RPPR. To reduce burden NIH will not require recipients to submit an additional Final-RPPR if the renewal application is not funded.

Grantees should refer to the funding opportunity to understand whether their application submission would be considered a renewal application or new.  For example, the funding opportunity announcement PAR-18-464 will receive renewal applications from grantees funded under PAR-15-304 and RFA-TR-14-009

Are there CTSA Program specific final RPPR instructions?

CTSA Program grantees should follow the CTSA Program Specific RPPR instructions for the final or interim RPPR and report on the progress for the prior budget year.  The format of the Interim RPPR and the Final RPPR will be the same as the current annual RPPR.

Differences between Interim/Final RPPR and the annual RPPR are few:

  • In the Interim/Final RPPR, only Section D.1 is required in the Participants section
  • Sections F: Changes and Section H: Budget are not part of the Interim/Final RPPR
  • Section I: Outcomes is new. Section I is required for both the Interim/Final RPPR

For more information about how to submit your final RPPR please see:

Grantees should be aware that the NIH will make the Project Outcomes Section of all Interim and Final RPPRs submitted on or after October 1, 2017 available via NIH RePORTER.  The narrative of the Project Outcomes section must be written for the general public in clear and comprehensible language, without including any proprietary, confidential information or trade secrets.  For more information see NOT-OD-18-103.